U.S. Patent Office Issues Vermillion Patent for Biomarkers Detecting Ovarian Cancer
News Nov 16, 2009
Vermillion, Inc. has announced that the U.S. Patent Office (USPTO) has issued patent number 7,605,003 titled "Use of biomarkers for detecting ovarian cancer" to the Company for the discovery of biomarkers for ovarian cancer.
The patent covers biomarker combinations for both the diagnosis and management of ovarian cancer and covers measurement of the markers by a variety of methods, including mass spectrometry and immunoassay approaches.
"Vermillion has been creating a comprehensive patent portfolio to protect our ovarian cancer testing franchise. The issuance of this patent supports our overall intellectual property strategy and we continue to pursue additional patent applications in support of our diagnostic programs," said Gail S. Page, Vermillion Executive Chairperson.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Simple Sugar Prevents Neurodegeneration in Lysosomal Storage DiseaseNews
New therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB)READ MORE
Eating Activates Calorie-Burning FatNews
The importance of the human brown adipose tissue (BAT) has become clearer during the past ten years. Coldness is one of the most effective activators of the BAT metabolic function but, in rodents, eating has also been shown to activate BAT. The debate on whether eating has the same effect on humans has lasted for decades. Now, the researchers at Turku PET Centre have proven that having a meal increases oxygen consumption in human BAT to the same extent as coldness.READ MORE